Resources

Accelerating Viral Vectors Commercialization to Market through Suspension Platform with Greater Predictability

Abstract: Developing innovative advanced therapies is one of our greatest opportunities to dramatically improve patients’ lives. In this webinar, we will discuss our recent technical advancement on efficient viral vector manufacturing process development. From cell line development, suspension culture of HEK293 cells, transfection, to cell culture optimization and purification process development, a series of progress …Read More >

Resource Type: Webinar
Resource Topic: Clinical & Commercial Manufacturing Process Development

VIEW

Accelerating Viral Vectors Commercialization through AAV Suspension Platform

  Summary of the Presentation given at Phacilitate in Miami (2020): – Established suspension HEK293 cell line – In-stock raw materials with established batch records – State-of-the-art GMP manufacturing facilities with enhanced scalability that range up to 1000L – Established and dedicated process & analytical development teams – Strong and dedicated technical guidance including regulatory …Read More >

Resource Type: Presentation
Resource Topic: Clinical & Commercial Manufacturing Process Development

VIEW

Poster: Accelerating Development and Manufacturing Platform for Viral Vector

Developing innovative advanced therapies is one of our greatest opportunities to dramatically improve patients’ lives. In this poster, we will discuss our recent technical advancement on efficient viral vector manufacturing process development. From cell line development, suspension culture of HEK293 cells, media optimization and purification process, a series of progress were implemented to advance our …Read More >

Resource Type: Poster
Resource Topic: Analytical Development Clinical & Commercial Manufacturing Process Development

VIEW

Roundtable Discussion: Cell and Gene Therapies — Keep the Work In-House, or Use a Third Party?

During BIO 2019, BioProcess International hosted a roundtable discussion on “Cell and Gene Therapies – Keep the work in-house or use a third party” at BPI Theater. It was moderated by BioProcess Insider editor Dan Stanton with industry leaders that included Felix Hsu, Senior Vice President and Global Head of WuXi Advanced Therapies, Celonic Group, …Read More >

Resource Type: Video
Resource Topic: Clinical & Commercial Manufacturing

VIEW

Multibillion-Dollar Race for Gene Therapy Manufacturing

“Gene therapy, a promising therapeutic approach that corrects disease-causing genetic errors, has spurred an arms race among the world’s largest pharmaceutical companies. Novartis (NYSE: NVS) announced the acquisition of AxeVis for a whopping $8.7 billion in 2018. Roche (NASDAQOTH: RHHBY) agreed to acquire gene therapy developer Spark Therapeutics for $4.8 billion in early 2019. One week …Read More >

Resource Type: Article
Resource Topic: Clinical & Commercial Manufacturing

VIEW